Schizophrenia is a polygenetic disease, the heterogeneity of which is likely complicated by epigenetic modifications yet to be elucidated. Here, we performed transcriptomic analysis of peripheral blood RNA from monozygotic twins discordant for schizophrenia and identified a schizophrenia-associated down-regulated microRNA, miR-501-3p. We showed that the loss of miR-501-3p in germline knockout (KO) male mice resulted in dendritic structure defects, glutamatergic transmission enhancement, and sociability, memory, and sensorimotor gating disruptions, which were attenuated when miR-501 expression was conditionally restored in the nervous system. Combining the results of proteomic analyses with the known genes linked to schizophrenia revealed that metabotropic glutamate receptor 5 (mGluR5) was one of the miR-501-3p targets and was elevated in vivo upon loss of miR-501. Treatment with the mGluR5 negative allosteric modulator 3-2((-methyl-4-thiazolyl) ethynyl) pyridine or the N -methyl- d -aspartate receptor antagonist 2-amino-5-phosphonopentanoic acid ameliorated the deficits observed in Mir501 -KO mice. The epigenetic and pathophysiological mechanism that links miR-501-3p to the modulation of glutamatergic transmission provides etiological implications for schizophrenia.
Objective: Cognitive impairment and depression significantly reduce quality of life in the aging population. This study aimed to investigate the prevalence of depressive symptoms and cognitive impairment and explore its relationship in the elderly. Methods: A total of 1645 elderly people in nursing homes and 4703 elderly people in the community were enrolled in the survey. The Patient Health Questionnaire-9 and Ascertain Dementia-8 were employed to evaluate depressive symptoms and cognitive impairment. Results: The overall prevalence of cognitive impairment was 12.5% in the community-dwelling group and 52.2% in the nursing home group. The prevalence of cognitive impairment in nursing homes was significantly higher than that in community-dwelling groups for the same age group (p < 0.001). The overall prevalence of depressive symptoms was 3.9% in the community-dwelling group and 2.0% in the nursing home group. The prevalence of depressive symptoms increased with age in the community-dwelling group (p < 0.001). The binary logistic regression results showed that the type of care mode affected the prevalence of cognitive impairment, and the elderly in nursing homes had a high risk of cognitive impairment (odds ratio [OR] = 3.528, 95% confidence interval [CI]: 2.209–5.635, p < 0.001); depressive symptoms had a significant positive correlation with the odds of cognitive impairment (OR = 1.854, 95% CI: 1.052–3.266, p < 0.05); and the cognitive impairment rate increased with age (OR = 1.412, 95% CI: 1.044–1.910, p < 0.05). Conclusions: There was an increased prevalence in cognitive impairment as well as depressive symptoms in the aging population in Zhongshan city. Population-based mental health strategies need to be urgently implemented for the aging.
Schizophrenia is a serious mental disorder with complex clinical manifestations, while its pathophysiological mechanism is not fully understood. Accumulated evidence suggested the alteration in epigenetic pathway was associated with clinical features and brain dysfunctions in schizophrenia. DNA methyltransferases (DNMTs), a key enzyme for DNA methylation, are related to the development of schizophrenia, whereas the current research evidence is not sufficient. The aim of study was to explore the effects of gene polymorphisms of DNMTs on the susceptibility and symptoms of schizophrenia. The study was case–control study that designed and employed the Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5) as the diagnostic standard. 134 hospitalized patients with schizophrenia in the Third People's Hospital of Zhongshan City from January 2018 to April 2020 (Case group) as well as 64 healthy controls (Control group) from the same region were involved. Single nucleotide polymorphisms (SNPs) of DNMT1 genes (r s2114724 and rs 2228611) and DNMT3B genes (rs 2424932, rs 1569686, rs 6119954 and rs 2424908) were determined with massARRAY. Linkage disequilibrium analysis and haplotype analysis were performed, and genotype and allele frequencies were compared. The Hardy–Weinberg equilibrium was tested by the Chi-square test in SPSS software (version 20.0, SPSS Inc., USA). The severity of clinical symptoms was assessed by the Positive and Negative Syndrome Scale (PANSS). The correlation between DNMT1 genes (rs 2114724 and rs 2228611) and DNMT3B genes (rs2424932, rs1569686, rs6119954 and rs2424908) and clinical features was analyzed. There were no significant differences in genotype, allele frequency and haplotype of DNMT1 genes (rs 2114724 and rs 2228611) and DNMT3B genes (rs 2424932, rs 1569686, rs 6119954 and rs 2424908) between the case and healthy control group. There were significant differences in the PANSS total positive symptom scores, P3 (hallucinatory behavior), P6 (suspicious/persecution), G7 (motor retardation), and G15 (preoccupation) in patients with different DNMT1 gene rs 2114724 and rs 2228611 genotypes. The linkage disequilibrium analysis of gene polymorphic loci revealed that rs 2114724–rs 2228611 was complete linkage disequilibrium, and rs 1569686–rs 2424908, rs 2424932–rs 1569696 and rs 2424932–rs 2424908 were strongly linkage disequilibrium. The polymorphisms alteration in genetic pathway may be associated with development of specific clinical features in schizophrenia.
22 June 2025 in International Journal of Developmental Neuroscience